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Editorial on the Research Topic
Placebo and Nocebo Effects in Psychiatry and Beyond
INTRODUCTION
The placebo effect is part of every medical intervention and plays a crucial role in randomized
placebo-controlled trials (RCTs). It is beneficial to maximize the placebo effect when treating
patients, but it should be minimized in RCTs to estimate the true drug effect (1). Studies have shown
that the placebo effect is formed by learning mechanisms (2), and an expert consensus has suggested
that the beneficial effects of placebo can be harnessed for clinical use to improve patient outcomes
(3). In contrast to the placebo effect, adverse events can occur and symptoms can get worse through
a negative placebo effect, the so-called nocebo effect (4). Yet, to exploit placebo mechanisms in
clinical practice a lot of questions remain unanswered. For this Research Topic Issue, we called for
the latest research articles in the field of placebo and nocebo research. The issue comprises 38
articles from “Hypothesis and Theory” to “Reviews” and to “Original Research” articles.
After giving an overview about the underlying mechanisms of the placebo effect, such as
conditioning, expectations and influencing factors, Friesen summarizes ethical views regarding the
use of the placebo effect. Until recently, it has been assumed that placebos take only effect when
patients are deceived, but she encourages considering placebos as a “source of agency”, without
deception and in agreement with patients’ autonomy. Babel complements the current view about
classical conditioning in the placebo effect. In fact, many studies use a combination of classical
conditioning and verbal suggestions to induce placebo and nocebo effects. Due to recent studies
using hidden and subliminal conditioning procedures, Babel argues that classical conditioning is ag August 2020 | Volume 11 | Article 8011
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However, there are only a few studies limited to the area of pain
and further studies are needed.THE PLACEBO EFFECT IN
PSYCHOTHERAPY
Particularly in psychiatry, patients are not only treated with
pharmacotherapy but often with different forms of
psychotherapy. The role and mechanisms of the placebo effect
in psychotherapy has been repeatedly discussed, and Enck and
Zipfel point to the challenges of disentangling specific effects of
the different psychotherapeutic approaches including unspecific
and the placebo effect. This is even more challenging
when considering that many psychotherapeutic approaches
are equally effective and there is still a debate within
psychotherapy research about the specific, common and
unspecific factors (also known as the “Dodo bird verdict”).
Enck and Zipfel encourage psychotherapy researchers as well
as therapists to understand that the placebo effect exists and
provide a framework that acknowledges context, common, and
specific factors for further research. With her Mini Review,
Blease attempts to provide greater clarity in the definition of
the placebo effect in psychotherapy and gives insights into
controversial views such as “psychotherapy is a placebo”. She
argues that the problem could be solved when placebos and the
placebo effect are clearly defined the same way as they are defined
in clinical trials: as control interventions and the effect they
induce. In the first instance, it seems to be contradictory that
Blease recommends using a clear definition of the placebo effect,
whereas Jonas states that “the placebo response is a myth” and
does not exist. According to his arguments it is contradictory
that an inert treatment will produce a response and votes for a
broader understanding of this response that should be called
“meaning response” or “healing response”. However, these two
views are compatible and in line with the definitions of “placebo
effect” as the effect elicited by placebo mechanisms, and “placebo
response” as all health changes after administration of an inert
treatment, as stated by expert consensus of placebo researchers
published in 2018 (3).THE ROLE OF CONTEXT FACTORS IN
PLACEBO AND NOCEBO EFFECTS
In psychotherapy research, context factors such as the patient-
provider interaction are considered a common factor, albeit they
are considered to be part of the placebo response in other
treatments. In their systematic review, Daniali and Flaten
found that aspects of a positive patient-provider interaction
such as higher confidence in the provider, perceived higher
competence and professionalism, and positive nonverbal
behaviors were associated with lower pain reports and higher
placebo effects in patients and participants. In contrast, negative
nonverbal behaviors led to higher pain reports and noceboFrontiers in Psychiatry | www.frontiersin.org 2effects. Howe et al. delve deeper in specific aspects of the
patient-provider-interaction and differentiate between
competence and warmth. They provide a framework for
researchers and practitioners about how patients perceive
competence and develop the feeling that the physician “gets it”,
and how they perceive warmth when the physician “gets them”.
However, non-specific effects of treatments comprise many
aspects, and Gerger et al. translated and validated the first
German version of the Healing Encounters and Attitudes Lists
(HEAL-D) and its short form (HEAL-D-SF). This set of
questionnaires assesses patients’ views on the patient-provider
interaction, the healthcare environment, treatment expectations,
positive outlook, spirituality, and attitudes towards
complementary and alternative medicine. It may help to turn
non-specific into specific effects, and therefore may be usable for
research purposes and clinical practice.
To evaluate how and how often oncologists make use of
empathy expressions by practitioners, van Vliet et al. assessed
video-taped consultations between oncologists and patients with
advanced breast cancer in an observational study. Overall,
oncologists often provided information about expectancy and
used several empathic behaviors such as understanding,
respecting, supporting and exploring, whereas a lack of
empathy was less often observed. Further studies should
evaluate effects of empathic expressions on treatment outcomes
and (nocebo) side effects. Not only physicians are aware of the
effect of unspecific factors on treatments, patients are aware of
them, too: In their large online survey among Italian patients
with musculoskeletal pain, Rossettini et al. found that patients
believe that contextual factors such as an empathetic alliance,
and verbal and non-verbal communication are effective and
work through mind-body connections. Furthermore, they have
positive attitudes towards their use in clinical practice if they are
not used in a deceptive way.
One of the challenges in placebo research is to disentangle the
placebo effect from other effects through elaborate study designs.
To differentiate the placebo effect from the psychosocial context,
Gruszka et al. as well as Curkovic et al. recommend outsourcing
some parts of the psychosocial context via smartphone
applications. Such an app could be used for standardized
recruitment, randomization and the provision of treatment
information to induce positive expectations. Furthermore, it
could be used to assess expectations, symptom severity, or
physiological data via smartphone sensors (e.g., heart rate)
without personal interaction and in daily life. Additionally,
Curkovic et al. suggest that studies should rigorously investigate
and report aspects of research plans to the better investigate which
aspects of an intervention at which dose is relieving symptoms,
and this could also be achieved through an app.THE PLACEBO EFFECT ON DEPRESSION,
ANXIETY, PAIN, AND OTHER SYMPTOMS
Irving Kirsch published several studies and meta-analyses about
the placebo response and placebo effect in treatments withAugust 2020 | Volume 11 | Article 801
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and the drug effect in RCTs are additive (5, 6). In his recent
article, Kirsch summarizes the results of these and other meta-
analyses clearly demonstrating that “most (if not all) of the
benefits of antidepressants in the treatment of depression and
anxiety are due to the placebo response”. However, RCTs cannot
answer the question how patients’ symptoms evolve without any
treatment or how they should be treated instead. Kirsch reports
several alternative treatments such as psychotherapy, physical
exercise, omega-3 supplements, and yoga that has been shown to
be as effective as antidepressants but with less side effects, and in
some cases with better long-term effects than antidepressants. To
further evaluate how expectancy could influence outcomes in
antidepressant trials, Laferton et al. performed a re-analysis of a
double-blind RCT in major depression comparing escitalopram,
S-adenosyl-L-methionine (SAMe) and placebo. Results show
that the patients’ perceived treatment assignment during the
trial changed, was predicted by symptom improvements, and
contributed more to treatment outcomes than actual treatment.
Finally, there was no difference between groups.
But patients do not only “feel better” through the placebo
effect, several neuroimaging studies could demonstrate
neurophysiological changes in the brain. Brown and Pecina
underline these results and provide an overview of
neuroimaging studies of the antidepressant placebo effect. They
show that this effect is comparable to the placebo effect on pain.
This finding implies common underlying mechanisms involving
brain areas associated with cognitive control, the representation
of expectations, and reward and emotional processes.
Still, pain is the best investigated symptom in placebo research.
Complementary to neuroimaging studies, Reicherts et al. present an
electroencephalography (EEG) study combining the motivational
priming hypothesis and the conditioning of placebo and nocebo
effects. Participants who were told that unpleasant pictures decrease
pain, indeed reported less pain, and consequently, somatosensory
evoked potentials were decreased when they watched unpleasant
pictures compared to neutral pictures. They conclude that the
well-known modulation of pain by emotions is influenced
by expectations.
The experimental pain study by Zhou et al. found
interactional effects of different expectations, sex of participants
and personal characteristics such as dispositional optimism and
state anxiety on pain reports in a complex manner. After a
conditioning procedure with electrical pain, women in the low
expectancy group reported decreased pain compared to the No
or High expectancy groups, whereas men reported decreased
pain in the High expectancy group in the test session. Whether
optimism or state anxiety predicted placebo effects was
dependent on the expectancy level, but independent of sex. To
explore other predictors of placebo analgesia, Wang et al. used
latent class analyses (LCA) to identify learning patterns during a
conditioning procedure in an experimental pain study. LCA
revealed that greater or increased differences between high
and low pain ratings in combination with red and green light
signaling stimuli during conditioning were associated with
greater placebo analgesia in the subsequent testing phase.Frontiers in Psychiatry | www.frontiersin.org 3Furthermore, expectations of pain decrease were a mediator for
placebo analgesia, but higher age and higher warmth-detection
thresholds were associated with lesser placebo analgesia.
A large proportion of our knowledge about the placebo effect
and its underlying mechanisms stems from experimental
studies with pain, but there is little knowledge whether the
same mechanisms apply to other symptoms. To elucidate this
question, Wolters et al. reviewed the literature about placebo
and nocebo effects in dyspnea, fatigue, nausea, and itch. They
can confirm that in general the same mechanisms as in pain are
at work in these symptoms, such as the combination of verbal
suggestions and conditioning, and that subjective symptoms
are more prone to elicit a placebo effect than are physiological
measures. However, there are also some differences as
the influence of individual characteristics varies between
symptoms. Evidence can be added by an experimental study
by Meeuwis et al. who investigated placebo and nocebo effects
through verbal suggestions on itch. Participants received the
respective information either in an open-label condition
knowing that the applied tonic was a placebo (a pink-colored
skin disinfectant), or in a closed-label condition in which they
were deceptively told that the tonic was effective. Whereas
suggestions did not affect itch reports during histamine
iontophoresis, participants in both positive suggestion groups
reported lower itch and lower skin temperature increase after
the iontophoresis compared to the negative suggestion groups.
Interestingly, their open-label suggestion was as effective as the
deceptive information about the effectiveness of the placebo,
and they found a symptom specific physiological reaction
to itch.
Another underreported areas are placebo and nocebo effects
on cardiac symptoms and physiology. In an experimental study
with patients with Takotsubo cardiomyopathy—a rare, reversible
form of cardiomyopathy after stressful psychosocial life events—
and heart-healthy controls, all participants received a saline
infusion three times together with the information that it has
no effect, a positive (placebo) or negative (nocebo) effect on
cardiac functions, respectively. Olliges et al. report that before
and during the nocebo condition subjective stress rating, heart
rate, and systolic blood pressure increased, whereas the latter also
increased after placebo information. However, there were no
differences between patients and controls.AREAS RELATED TO MENTAL
DISORDERS
The placebo effect could not only be helpful to directly decrease
symptoms of a disorder, but also when it is used to influence
functions related to mental disorders such as cognitive
functioning or appetite regulation. Participants in the study
of Fuhr and Werle were randomized to listen to a mental
training or philosophy lecture both audio-taped for 20 min, and
half of the participants of each group were told that they listen
to an effective or control tape. All participants improved their
cognitive performance as measured with a d2-test, but thoseAugust 2020 | Volume 11 | Article 801
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received treatment as effective irrespective of group assignment.
This, at least, shows that healthy persons can rate their
cognitive performance without being influenced by (bogus)
verbal suggestions, and thus, could be indicative of a healthy
function. Winkler and Hermann chose a different study design:
two groups received a nasal spray along with the suggestion of a
cognitive improvement (placebo) or impairment (nocebo)
effect, and one group served as a control (without nasal spray
or suggestions). Similar to the study by Fuhr and Werle, verbal
suggestions did not affect actual cognitive performance.
However, participants in the placebo group rated their
cognitive improvement better and felt less tired compared to
the nocebo group. The authors conclude that these subjective
effects may explain why so-called neuroenhancers are still
popular among college students. For their study about
placebo and nocebo effects of a sham transcranial magnetic
stimulation (sTMS), Höfler et al. employed women who turned
out to be placebo or nocebo responders, respectively, in previous
studies. According to their responsiveness they received the
information that the sTMS will increase (placebo) or decrease
(nocebo) their left-sided visual attention in an eye-tracking
experiment. As in the above-mentioned studies, the placebo
instruction did not affect actual visual attention, but subjectively
improved attention. In contrast, nocebo responders showed the
opposite to the expected reaction.
In another eye-tracking study from the same work group,
Potthoff et al. did not directly target visual attention, but a
placebo pill that claimed to reduce appetite was given to
healthy, mostly normal-weight women, and their reactivity to
food cues was registered. Participants reported decreased
appetite which was related to decreased visual attention for
food, e.g., fixation and dwell time on high and low-caloric food
images compared to non-food pictures. The experimental study
by Hoffmann et al. confirms these results: healthy normal-weight
participants reported decreased appetite after ingesting a placebo
pill that should increase satiety compared to a control group.
They additionally assessed an objective marker of hunger and
found that the opposite information—that a placebo pill claimed
to enhance appetite - increased plasma ghrelin levels but did not
affect appetite itself. In a third study of placebo effects on food
consumption, Panayotov showed that the information about a
calorie-reduced diet decreased body mass, body mass index
(BMI), and fat tissue in overweight and obese participants of a
weight loss program. Although participants did not strictly
adhere to their diet programs and the sample size was small,
this preliminary study shows that weight regulation could be
directly addressed through manipulating expectations
of patients.NOCEBO EFFECTS
In conjunction with studies about the placebo effect, the nocebo
effect has already been mentioned above. Previous studies aboutFrontiers in Psychiatry | www.frontiersin.org 4the “bad brother” of the placebo effect have shown that known
placebomechanisms such as conditioning, expectations, and social
learning can also have negative outcomes. Faasse et al. define
“nocebo effects as unpleasant or adverse outcomes triggered by the
treatment context”. The authors differentiate between primary
nocebo effects and nocebo side effects, and the misattribution of
regular symptoms to an (inert) treatment. Furthermore, they
describe how experimental studies should be designed to
investigate the nocebo effect appropriately. While Faasse et al.
focus on studies with treatments involving drugs or medical
devices, Locher et al. emphasize that the nocebo effect could also
occur in psychotherapy. They provide two examples where a nocebo
or nocebo-related effect could evolve: In patients with chronic
primary pain or other symptoms without a clear physiological
etiology, and in relation to trauma debriefing to prevent post-
traumatic stress disorders (PTSD).
To prevent nocebo (side) effects it would be helpful if nocebo
responders could be detected in advance. In a re-analysis of
experimental endotoxemia studies, Benson and Elsenbruch
investigated predictors of the nocebo effect. Nocebo responders,
defined as participants in the placebo arms of RCTs who believed
they were allocated to the verum arm, reported significantly more
physical symptoms but did not differ from non-responders in
psychological or physical parameters. Within nocebo responders,
physical symptoms correlated with greater state anxiety,
negative mood, catastrophizing and neuroticism. Their study
demonstrates that it is difficult to predict who will be a nocebo
responder, but that perceiving nocebo side effects could affect
perceived treatment allocation—another reason why nocebo side
effects should be reduced. Webster and Rubin provide a
systematic review of RCTs investigating brief psychological
interventions to reduce or avoid nocebo side effects in medical
treatments. In the 27 studies found, omitting side effect
information was most successful to reduce nocebo side effects,
whereas other communication strategies such as priming,
distraction, and altering the branding of drugs showed mixed
effects. De-emphasizing of side effects was not effective. Finally,
they discuss that it could be challenging to balance the reduction
of nocebo side effects with informed consent. Pan et al.
investigated another strategy to reduce nocebo side effects in an
experimental study: Participants with weekly headaches received
a placebo pill and were randomized to read a bogus medication
leaflet only or to read additionally an explanation about the
nocebo effect. Two minutes after pill intake, the group that had
received the explanation about nocebo reported less nocebo
symptoms than the other group. This effect was moderated by
baseline symptoms, perceived sensitivity to medicine, and
expectations. Furthermore, most participants evaluated the
nocebo information as helpful.UNDERREPORTED RESEARCH FIELDS
Most of the articles in this Research Topic deal with the placebo
effect and response after typical applications of treatments suchAugust 2020 | Volume 11 | Article 801
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effect from the placebo response and placebo effect is also
challenging in other forms of treatments, e.g., psychotherapy
(see above). Chae et al. discuss in particular two aspects that
could lead to a high placebo response in acupuncture: the fact
that even sham acupuncture may elicit physiological responses,
and the difficulty of effective blinding of provider and patient.
They suggest more appropriate alternative control strategies in
acupuncture treatment.
There is less research about the placebo effect in children (7) and
this Research Topic comprises only two further articles about it: one
involved an experimental design with healthy children, and one
discusses the influence of the so-called placebo-by-proxy effect. The
placebo-by-proxy effect was introduced by Grelotti and Kaptchuk
(8) in 2011 and describes the effect where people in the social
environment of a patient (parents, siblings, relatives, peers) feel
better when the patient receives an effective treatment. Czerniak
et al. complement this concept with the corresponding “nocebo-
by-proxy” effect and discusses the impact of these two concepts
particularly on children’s symptoms and treatments. Their
review of the available literature opens an important research
field. The influence of parents or other proxies on placebo and
nocebo responses has rarely been studied. The experimental
study by Watolla et al. investigated the effect of a suggested
ginkgo patch on cognitive performance in children and one
parent. While they found only a poor overall placebo effect,
neither the cognitive performance nor the expectations of
children and their parents were interrelated. This may imply
that shared information and heritability have a low impact on the
placebo effect. Although it should be taken into account that the
participants were all healthy and without need for cognitive
improvement. This finding is supported by the first study
involving a classical twin design: Weimer et al. employed
healthy mono- and dizygotic twin pairs in an experimental
study with a heat pain paradigm. After conditioning the
effectiveness of an ointment, twins reported a significant
placebo analgesic effect in the test condition. This effect was
mainly related to the personal learning experience during the
conditioning procedure, but not to the effect of their co-twin,
suggesting that heritability and shared environment play a minor
role. In contrast, first studies show a genetic component in the
placebo effect, but these results are still inconclusive (9) and twin
studies should be combined with genetic analyses to further
elucidate this area.MAXIMIZE OR OPTIMIZE TREATMENTS
THROUGH PLACEBO MECHANISMS
Elsenbruchetal. tie in with first evidence that psychophysiological
responses, such as an increase of parasympathetic activation, to
placebo interventions could play a role in the establishment of a
placebo effect. In their study, a brief progressive muscle
relaxation exercise but not a control task reduced heart rateFrontiers in Psychiatry | www.frontiersin.org 5and systolic blood pressure, and decreased pain perceptions in
relaxed participants in a pain paradigm with rectal distensions.
Such experimental studies show promising ways to harness
the placebo effect for patients’ treatments in ethical and legal
ways. Benefits for patients are clear as they experience symptom
as well as side effect reductions, but the placebo effect is rarely
used systematically. Showing that harnessing the placebo effect is
not only effective but also cost-efficient could improve its
visibility and acceptability. A systematic review by Hamberger
et al. investigated if placebo interventions are also cost-efficient
but showed that there is a lack of health economic evaluations
and encourage placebo researchers to report costs of
placebo interventions.CONCLUSION: MORE QUESTIONS THAN
ANSWERS?
In summary, the multifaceted articles in this Research Topic
issue show that placebo and nocebo effects are complex
phenomena. There is still a debate about the role of placebo
and nocebo effects in psychotherapy research and their relation
to common and context factors. In contrast, context factors such
as the patient-provider interaction have already been
acknowledged as part of the placebo effect in other treatments.
Research about the placebo effect on depression, anxiety, and
pain reveals a high placebo effect showing symptom
improvement and neurophysiological changes in the brain.
However, there is less research about other symptoms such as
itch or heart-related diseases, among others. Recent studies aim
to harness the placebo effect to improve functions that are related
to mental disorders, such as cognitive functioning or appetite
regulation, and may be an interesting research area for further
studies. There are several other underreported research fields
such as: appropriate control conditions for treatments other than
pills, placebo and nocebo effects in children, and the role of
genetics and heritability. An increasing amount of articles
investigate the nocebo effect and nocebo related adverse effects,
their mechanisms and strategies to avoid or reduce them. Finally,
all research aims to improve treatments of patients and recent
studies show promising results by employing techniques that
enhance the placebo effect or reduce the nocebo effect. However,
more research is needed to transfer knowledge about placebo and
nocebo effects into clinical practice to benefit patients in an
ethical and broadly accepted manner (10).AUTHOR CONTRIBUTIONS
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